The following rewrite preserves original meaning and key information while presenting it in fresh wording, expanded where helpful, and with a tone that is friendly, professional, and accessible for beginners. It begins with a provocative hook to draw readers in and invites discussion at the end.
Bold opening statement: BRCA-mutated mCRPC patients across every age bracket can benefit from rucaparib, not just younger patients. But here’s where it gets controversial: does age truly influence how well this drug works, or is that perception shaped by other factors like comorbidities and prior therapies? The updated TRITON3 data provide a clear, age-spanning signal that rucaparib offers meaningful radiographic progression-free survival (rPFS) advantages regardless of age, reinforcing its role as a robust treatment option.
Overview of the latest TRITON3 findings
- In BRCA-mutated metastatic castration-resistant prostate cancer (mCRPC), rucaparib significantly improved rPFS compared with physician’s choice of docetaxel or second-generation androgen receptor pathway inhibitors (ARPI), across all age groups. These results come from the phase 3 TRITON3 trial (NCT02975934).
- Across the overall BRCA-mutated cohort (n = 201 on rucaparib vs n = 101 on physician’s choice), median rPFS was 11.2 months with rucaparib compared with 6.4 months for the comparator (hazard ratio [HR] 0.50; 95% CI, 0.36–0.69).
Age-stratified outcomes
- Under 65 years: median rPFS was 11.2 months with rucaparib vs 6.3 months with comparator (HR, 0.60; 95% CI, 0.33–1.08).
- 65–74 years: median rPFS was 11.2 months with rucaparib vs 7.6 months with comparator (HR, 0.46; 95% CI, 0.28–0.75).
- 75 years and older: median rPFS was 11.2 months with rucaparib vs 5.4 months with comparator (HR, 0.41; 95% CI, 0.22–0.74), reflecting a 59% relative reduction in the risk of radiologic progression.
Key takeaways from TRITON3 (updated data with rucaparib in mCRPC)
- Consistent improvement in rPFS with rucaparib versus physician’s choice across all age groups in BRCA-mutated mCRPC.
- The relative benefit appeared greatest in the oldest group (≥75 years), demonstrating a 59% reduction in radiologic progression risk.
- Safety remained manageable. Common adverse events included fatigue and anemia, with no major age-related safety concerns beyond higher anemia rates in older patients.
Expert interpretation
“These findings support the use of rucaparib as a treatment option in patients with BRCA-mutated mCRPC independent of age,” wrote Alan H. Bryce, MD, and colleagues in a poster detailing the TRITON3 results.
What TRITON3 looked at and how it was designed
- Study design: Open-label, randomized, phase 3 trial enrolling chemotherapy-naive mCRPC patients with BRCA1/2 or ATM alterations who previously received a second-generation ARPI. Participants were randomized in a 2:1 ratio to receive 600 mg rucaparib twice daily (n = 270) or physician’s choice (n = 135), which could include docetaxel (n = 75) or another ARPI such as abiraterone acetate or enzalutamide (n = 60).
- Stratification factors included ECOG performance status (0 vs 1), liver metastases (presence vs absence), and mutational subtype (BRCA1 vs BRCA2 vs ATM).
- Primary endpoint: rPFS assessed by blinded independent central review (BICR). Secondary endpoints included overall survival (OS) and objective response rate (ORR) by BICR.
- Longitudinal results: At 62 months, the overall analysis showed a meaningful prolongation of imaging-based PFS with rucaparib versus physician’s choice (HR 0.61; P < .001 in the intention-to-treat population).
Subgroup signals and mutation-specific observations
- ATM-mutated subgroup: Median imaging-based PFS was 8.1 months with rucaparib vs 6.8 months with comparator (HR 0.95; 95% CI, 0.59–1.52).
- BRCA-mutated subgroup: Median OS favored rucaparib (24.3 months) vs comparator (20.8 months) with HR 0.81, although the p-value did not reach conventional levels of statistical significance in this analysis (P = .21).
Additional context and regulatory backdrop
- In May 2020, the FDA granted accelerated approval for rucaparib (Rubraca) for BRCA mutation–associated mCRPC after AR-directed therapy and taxane exposure, based on earlier findings from the TRITON2 trial (phase 2), which showed an objective response rate of 44% among evaluable patients.
- The TRITON3 analyses add depth by exploring how age interacts with clinical benefit, indicating that older patients can reap substantial rPFS advantages with rucaparib.
Baseline characteristics by age group (highlights)
- Age <65: Median ages around 59–61 across arms; most participants were White; metastatic patterns and prior therapies varied, but many had bone metastases and multiple prior mCRPC-directed therapies.
- Age 65–74: Median ages around 69–70; similar disease burden with high rates of bone metastases and prior ARPI exposure; a sizable portion had prior docetaxel in some settings.
- Age ≥75: Median ages around 78–79; notable representation of White patients; ECOG performance status commonly 1 in this group; bone and nodal metastases were prevalent, with substantial prior ARPI and taxane exposure reported.
Safety profile by age
- The most frequent TEAEs with rucaparib included fatigue (asthenia), anemia, nausea, decreased appetite, and diarrhea. Anemia tended to worsen with age, and a higher rate of anemia was observed in older patients overall. Declines in appetite were more common with advancing age in the rucaparib arm. Overall, no new age-specific safety signals emerged beyond these patterns.
Caveats and interpretations
- While several age-stratified results suggest stronger relative risk reductions in older groups, interpretation should consider the study’s design, sample sizes within subgroups, and the potential impact of prior treatments and comorbidities on outcomes.
Bottom line
Rucaparib demonstrates a meaningful and broadly consistent rPFS benefit in BRCA-mutated mCRPC across age groups, including patients aged 75 and older, with a safety profile that remains manageable. These findings support using rucaparib as a treatment option for BRCA-mutated mCRPC irrespective of patient age, while also inviting further discussion about tailoring therapy to individual patient contexts.
Discussion prompts for readers in the comments
- Do you find the age-related signal convincing enough to influence practice in older patients with BRCA-mutated mCRPC?
- How might prior ARPI exposure or comorbidities confound the apparent age effect observed in TRITON3?
- In your practice, would you consider rucaparib earlier or later in the treatment sequence based on this data? Share your experiences and viewpoints.
